Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE:SEM) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, which applies to the proposed acquisition of Select Medical by a wholly owned subsidiary of WCAS XIV, L.P., an investment fund affiliated with Welsh, Carson, Anderson & Stowe ("WCAS") and a member of a consortium (the "Consortium") led by Robert A. Ortenzio, Executive Chairman, Co-Founder and Director of Select Medical, and Martin F. Jackson, Senior Executive Vice President of Strategic Finance and Operations of Select Medical (such transaction, the "Merger"), expired at 11:59 p.m. Eastern Time, on April 27, 2026. The Merger is expected to close mid-2026, subject to the approval of Select Medical's stockholders (including the approval of a majority of shares not held by the Consortium or its affiliates) and satisfaction of other customary closing conditions.